Cloperastine Hydrochloride

https://huagongshe.com/de/chemical/161104

Identifikatoren & physikalische Daten

CAS No.	14984-68-0
Summenformel	C20H25Cl2NO
Durchschnittliche Molmasse	366,3 g/mol
Monoisotopische Masse	365,1313198 g/mol
SMILES	Cl.Clc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1
InChIKey	UNPLRYRWJLTVAE-UHFFFAOYSA-N
PubChem CID	161104
ChEMBL	CHEMBL1492516
ChEBI	CHEBI:31420
EC No.	239-067-8
DTXSID	DTXSID5045413

Chemische & physikalische Eigenschaften

Polarare Oberfläche (TPSA)	12,5
H-Brücken-Donoren	1
H-Brücken-Akzeptoren	2
Frei drehbare Bindungen	6
Schwere Atome	24
Formalladung	0
Komplexität	318
Collision Cross Section	180.4 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]

Sicherheit & Vorschriften

GHS-Einstufung	WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 42 reports by companies from 3 notifications to the ECHA C&L Inventory.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Hazard Classes and Categories	Acute Tox. 4 (100%)
Effects During Pregnancy and Lactation	◉ Summary of Use during LactationCloperastine is not marketed in the United States, but is available in other countries. No information is available on the clinical use of cloperastine during breastfeeding. Long-term use of cloperastine might reduce milk production or milk letdown. During long-term use, observe for signs of decreased lactation (e.g., infant insatiety, poor weight gain).◉ Effects in Breastfed InfantsRelevant published information was not found as of the revision date.◉ Effects on Lactation and Breastmilk

CAS No.

14984-68-0

Summenformel

C20H25Cl2NO

Durchschnittliche Molmasse

366,3 g/mol

Monoisotopische Masse

365,1313198 g/mol

SMILES

Cl.Clc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1

InChIKey

UNPLRYRWJLTVAE-UHFFFAOYSA-N

PubChem CID

161104

ChEMBL

CHEMBL1492516

ChEBI

CHEBI:31420

EC No.

239-067-8

DTXSID

DTXSID5045413

Polarare Oberfläche (TPSA)

12,5

H-Brücken-Donoren

H-Brücken-Akzeptoren

Frei drehbare Bindungen

Schwere Atome

Formalladung

Komplexität

318

Collision Cross Section

180.4 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]

Sicherheit & Vorschriften

GHS-Einstufung

WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 42 reports by companies from 3 notifications to the ECHA C&L Inventory.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Hazard Classes and Categories

Acute Tox. 4 (100%)

Effects During Pregnancy and Lactation

◉ Summary of Use during LactationCloperastine is not marketed in the United States, but is available in other countries. No information is available on the clinical use of cloperastine during breastfeeding. Long-term use of cloperastine might reduce milk production or milk letdown. During long-term use, observe for signs of decreased lactation (e.g., infant insatiety, poor weight gain).◉ Effects in Breastfed InfantsRelevant published information was not found as of the revision date.◉ Effects on Lactation and Breastmilk